Changes in DNA methylation profiles of myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions

Table 1 Summary of sequencing data and Bismark alignment output

Sample ID	Total reads	Map. effic %	MethylC CpG %	MethylC CpHpG %	MethylC CpHpH %	Conv. rate %
Control 1	9,221,090	49	39	1	0	100
Control 2	14,000,485	28	39	1	1	99
Control 3	15,237,052	45	41	1	0	100
Control 4	16,305,850	45	48	1	1	99
Control 5	14,146,640	50	41	1	1	99
Control 6	17,961,183	26	39	0	0	100
Control 7	21,023,385	12	42	0	0	100
Control 8	14,287,174	45	40	1	1	99
Control 9	14,605,142	29	40	0	0	100
Control 10	19,983,522	49	50	1	1	99
Patient 1	20,739,258	25	42	0	0	100
Patient 2	12,830,866	51	38	1	1	99
Patient 3	16,521,910	34	43	1	1	99
Patient 4	16,888,563	30	39	1	1	99
Patient 5	13,589,812	51	42	0	0	100
Patient 6	14,374,956	49	43	0	0	100
Patient 7	21,391,108	40	39	1	0	100
Patient 8	13,587,009	37	41	1	1	99
Patient 9	13,261,182	28	61	1	1	99
Patient 10	20,052,690	46	45	1	1	99

Each sample, as identified by sample ID, has corresponding data showing, total reads, mapping efficiency from bismark, methylated cytosines in three different contexts (CpG, CpHpG and CpHpH). H can be either A, T or C, and the percentage is calculated individually for each context following the equation: % methylation = 100 × methylated Cs/(methylated Cs + unmethylated Cs). The bisulphite conversion rate calculated as the average of the number of Ts (non-methylated Cytosines) divided by coverage for each non-CpG cytosine

ISSN: 1868-7083